鉴定和验证与免疫相关的长链非编码 RNA 标志物，用于预测膀胱癌患者的预后。

Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.

机构信息

Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

出版信息

Int Immunopharmacol. 2021 Jan;90:107146. doi: 10.1016/j.intimp.2020.107146. Epub 2020 Nov 11.

DOI:10.1016/j.intimp.2020.107146

PMID:33189610

Abstract

BACKGROUND

Recent studies have revealed the significant roles of immune-related long noncoding RNAs (lncRNAs) in cancer development and progression. The identification of biomarkers that contribute to early detection and risk stratification provides significant benefits for bladder cancer (BC) patients. The current study aimed to determine an immune-related lncRNA signature for predicting the prognosis of BC patients.

METHODS

Based on The Cancer Genome Atlas (TCGA) database, we identified seven immune-related lncRNAs with prognostic value. The predictive value of the prognostic signature developed from immune-related lncRNAs was assessed by survival and nomogram analyses. Principal component analysis (PCA) was performed to visualize gene expression patterns in the groups defined by the risk score, and the immune composition and purity of the tumor were evaluated by the ESTIMATE algorithm.

RESULTS

Based on the Pearson correlation analysis results, 765 immune-related lncRNAs were filtered (|R| > 0.4, P < 0.001), and seven immune-related lncRNAs (Z84484.1, AC009120.2, AL450384.2, AC024060.1, TNFRSF14-AS1, AL354919.2, OCIAD1-AS1) with prognostic value were finally identified. Patients in the low-risk group had a better prognosis than those in the high-risk group. Multivariate Cox regression analysis showed that the signature was an independent prognostic factor. A prognostic nomogram with clinical features and the signature of seven immune-related lncRNAs was also constructed. According to the PCA and ESTIMATE algorithm results, we found different immune statuses in the low-and high-risk groups.

CONCLUSIONS

Our study shows that the signature of seven immune-related lncRNAs can be used as a prognostic marker for BC.

摘要

背景

最近的研究揭示了免疫相关长非编码 RNA（lncRNA）在癌症发展和进展中的重要作用。鉴定有助于早期检测和风险分层的生物标志物可为膀胱癌（BC）患者带来重大获益。本研究旨在确定用于预测 BC 患者预后的免疫相关 lncRNA 特征。

方法

基于癌症基因组图谱（TCGA）数据库，我们确定了 7 个具有预后价值的免疫相关 lncRNA。通过生存和列线图分析评估了由免疫相关 lncRNA 开发的预后特征的预测价值。通过主成分分析（PCA）可视化按风险评分定义的组中的基因表达模式，并通过 ESTIMATE 算法评估肿瘤的免疫组成和纯度。

结果

基于 Pearson 相关分析结果，筛选出 765 个免疫相关 lncRNA（|R|>0.4，P<0.001），最终确定了 7 个具有预后价值的免疫相关 lncRNA（Z84484.1、AC009120.2、AL450384.2、AC024060.1、TNFRSF14-AS1、AL354919.2、OCIAD1-AS1）。低风险组的患者预后优于高风险组。多变量 Cox 回归分析表明，该特征是独立的预后因素。还构建了包含临床特征和 7 个免疫相关 lncRNA 特征的预后列线图。根据 PCA 和 ESTIMATE 算法结果，我们发现低风险组和高风险组之间存在不同的免疫状态。